Physician profile
Stanley Cohen
NPI 1316975840
$338,066.34
in general payments reported to CMS, 2019-2025
13 companies · $81K in 2025
The $81K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $15K · 2021: $36K · 2022: $40K · 2023: $59K · 2024: $62K · 2025: $81K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $161K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $12K · Travel and Lodging: $8,600 · Consulting Fee: $7,258 · Food and Beverage: $7,155 · Honoraria: $6,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $161,112.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $11,780.00 |
| Travel and Lodging | $8,600.49 |
| Consulting Fee | $7,257.50 |
| Food and Beverage | $7,155.37 |
| Honoraria | $6,202.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $125,404.13 | 2019-2025 | Epclusa, Vemlidy, Livdelzi |
| Abbvie INC. | $94,169.83 | 2019-2025 | Mavyret |
| Intercept Pharmaceuticals, INC. | $51,218.69 | 2019-2024 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $40,295.29 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $26,529.97 | 2024-2025 | Rezdiffra, Resmetirom |
| Echosens North America, INC. | $125.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $108.48 | 2019 | |
| Novo Nordisk INC | $102.39 | 2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $29.75 | 2022 | |
| Lilly USA, LLC | $27.98 | 2024 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $19.93 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.15 | 2019 | |
| Portola Pharmaceuticals, LLC | $15.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.